Background: The current study utilized a Bleomycin-induced model of skin fibrosis to investigate the neo-epitope\r\nCO3-610 (KNGETGPQGP), a fragment of collagen III released during matrix metalloproteinase-9 (MMP9) degradation\r\nof the protein, we have previously described as a novel biomarker for liver fibrosis. The aim was to investigate\r\nCO3-610 levels in another well characterised model of fibrosis, to better describe the biomarker in relation to\r\nadditional fibrotic pathologies.\r\nMethods: Skin fibrosis was induced by daily injections of Bleomycin to a total of 52 female C3 H mice, while\r\ncontrol mice (n = 28) were treated with phosphate buffered saline (PBS), for 2, 4, 6 or 8 weeks. Skin fibrosis was\r\nevaluated using Visiopharm software on Sirius-red stained skin sections. Urine ELISA assays and creatinine\r\ncorrections were performed to measure CO3-610 levels.\r\nResults: CO3-610 levels were significantly higher in Bleomycin-treated vs. PBS-treated mice at each time point of\r\ntermination. The mean increases were: 59.2%, P < 0.0008, at 2 weeks; 113.5%, P < 0.001, at 4 weeks; 136.8%, P <\r\n0.0001 at 6 weeks; 157.2%, P < 0.0001 at 8 weeks). PBS-treated mice showed a non-significant increase in CO3-610\r\nlevels (mean increase for weeks 2-8 = 1.7%, P = 0.789) CO3-610 levels assayed in urine were statistically\r\nsignificantly correlated with Western blot analysis showing increased skin fibrosis (P < 0.0001, r = 0.65).\r\nConclusion: Increased levels in mouse urine of the MMP-9 mediated collagen III degradation fragment CO3-610\r\nwere correlated with skin fibrosis progression, suggesting that CO3-610 may be a potential positive biomarker to\r\nstudy the pathogenesis of skin fibrosis in mice.
Loading....